SCHEMBL4215337

SCHEMBL4215337

COc1ccc(NS(=O)(=O)c2ccc(F)c(C(F)(F)F)c2)c2c1C[C@@H](N(C)C)CC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.56
QRFPR Q96P65 1/20 0.56
ERAP1 Q9NZ08 1/20 0.48
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
CCR2 P41597 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
PGAM1 P18669 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4197775 0.91 HTR6 (0.60) HTR6QRFPRLMNATP53THRB
SCHEMBL4209413 0.89 HTR6 (0.58) HTR6QRFPRLMNAKMT2ACHRM2
SCHEMBL4200847 0.88 HTR6 (0.62) HTR6QRFPRLMNATP53THRB
SCHEMBL4212808 0.86 HTR6 (0.61) HTR6QRFPRLMNATP53KMT2A
SCHEMBL4213931 0.85 HTR6 (0.56) HTR6QRFPRLMNAKMT2ACHRM2
SCHEMBL4207489 0.85 HTR6 (0.57) HTR6QRFPRLMNAALDH1A1CHRM2
SCHEMBL4197797 0.84 HTR6 (0.59) HTR6QRFPRALDH1A1CHRM2CHRM1
SCHEMBL4210386 0.84 HTR6 (0.55) HTR6QRFPRLMNAKMT2AALDH1A1
SCHEMBL4202605 0.84 HTR6 (0.56) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4202398 0.84 ERAP1 (0.47) HTR6QRFPRERAP1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885ERAP1 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.